C. Michael Gibson/LinkedIn; Ulf Landmesser/FRIEDE SPRINGER
Cardiovascular
Prevention
Center Charité
Nov 9, 2025, 12:33
C Michael Gibson and Ulf Landmesser Discuss Insights from CLOSURE-AF trial
C Michael Gibson, President and CEO at Baim Institute for Clinical Research, shared on LinkedIn:
”Dr. Ulf Landmesser and I discuss the CLOSURE-AF trial:
In AF patients with high risk of stroke and bleeding, is LAA occlusion as effective and safe compared to optimal medical therapy?
View it here.”
Stay updated with Hemostasis Today.
-
Oct 4, 2026, 12:36Maia Meier: Advancing Hemophilia Care in Nepal – Project Elevate Her Visits Civil Service Hospital
-
Oct 4, 2026, 12:30Shailaja Kota Amplifies World Inherited Blood Disorders Month and Global Action Network’s Call to Action
-
Oct 4, 2026, 12:21Davide Pallucci: How Altered Platelet Metabolism Can Drive Changes in their Reactivity in Human and Mouse MASLD
-
Oct 4, 2026, 11:02Stimuli-Induced Remodeling of the Platelet Lipidome in Pulmonary Embolism – ESC
-
Oct 4, 2026, 10:45Join the Bleeding Disorders Advocacy Network! – HFA
-
Oct 4, 2026, 06:12David McIntosh: 900 Plasma Donations One Patient One Lifeline
-
Oct 4, 2026, 06:00Aadil Sheikh: Menopausal Hormone Therapy and Thrombosis Rethinking Route Dose and Risk
-
Oct 4, 2026, 05:27Nirali Thakkar: Influenza and Myocardial Infarction An Unexpected Cardiovascular Connection
-
Oct 4, 2026, 05:03Hisham Fahmi: Thromboprophylaxis in Children With ALL A Risk Adapted Approach